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Fabry’s disease is an X-linked lysosomal storage disease caused by a
deficiency of a-galactosidase that results in an accumulation of neutral
glycosphingolipids throughout the body, including the cardiovascular
system. Fabry cardiomyopathy, characterized by progressive severe
concentric left ventricular (LV) hypertrophy, is very frequent and is the
most important cause of death in affected patients. Enzyme replacement
therapy (ERT) allows a specific treatment for this disease, however,
there are very few data on the effectiveness of therapy on cardiac
involvement. Nine patients with Fabry cardiac disease were studied on
basal condition and after 6 and 12 months of treatment with algasidase b
(Fabrazyme1). A complete clinical, electrocardiographic and
echocardiographic evaluation was performed in all patients.
Interpretable Doppler recordings of transmitral flow and pulmonary
flow velocity curves were also acquired. At baseline, the patients with
Fabry’s disease had increased LV septum and posterior wall thickness,
normal LV fractional shortening, LV ejection fraction, normal Doppler
parameters of mitral inflow but a duration of pulmonary vein flow
velocity wave exceeding that of the mitral wave at atrial systole. ERT did
not affect heart rate and arterial pressure. LV internal diameters did not
change, there was a slight but not significant decrease in the LV
posterior wall thickening and a progressive decrease in the
interventricular septum thickening (p< 0.025) and in LV mass
(p< 0.001) The difference in duration between pulmonary vein flow
velocity wave and mitral wave at atrial systole significantly decreased
(p< 0.001). These results suggest that ERT in patients with Fabry
cardiomyopathy is able to reduce the LV mass and ameliorate the LV
stiffness.
Fabry’s disease is an X-linked recessive disorder
of glycosphingolipid metabolism caused by defi-
ciency of the lysosomal enzyme a-galactosidase.
It is a rare panethnic disorder with an estimated
frequency of 1 in 1,17,000 male births (1). In fact,
a recent evaluation in Italy indicates about 150
subjects with a confirmed diagnosis of the dis-
ease. The disease is characterized by the progres-
sive intracellular accumulation of neutral
glycosphingolipids throughout the body, with
prominent involvement of the skin, vascular
endothelium, kidney, nervous system, and heart
(2). The median survival for hemizygous males is
50 years and 70 for obligate females with death
secondary to cerebrovascular disease and myo-
cardial infarction (3, 4). Fabry cardiomyopathy
is very frequent and is the most important cause
of death in affected patients (2, 5). Moreover, the
cardiac involvement can be the sole manifestation
of disease in male patients with specific gene
mutations and in female carriers with low enzym-
atic activity (‘cardiac Fabry variant’) (6, 7). The
isolated cardiac variant seems to be more com-
mon than previously thought, and around 3% of
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male patients with an unexplained left ventricular
hypertrophy (LVH) may suffer from this disease
variant (8). However, most patients with Fabry’s
disease do not experience cardiac symptoms until
late in the disease course. A common feature of
the Fabry cardiomyopathy is an LVH in the pre-
sence of a diastolic dysfunction with preserved
systolic function (9). Echocardiography allows
to obtain a reliable assessment of left ventricular
mass and of systolic and diastolic function.
Namely, the simultaneous analysis of mitral and
pulmonary vein flow velocity curves provides
information on left ventricular filling dynamics
(10, 11). Doppler-derived parameters of the first
diastolic phase are influenced by left ventricular
systolic function and are predictive of filling pres-
sures only in patients with depressed left ventri-
cular ejection fraction. On the contrary, Doppler
measurements of late diastole reflect left ventri-
cular end-diastolic pressure regardless of systolic
function (12).
Recent advances in molecular biology and
genetic engineering have enabled the develop-
ment of enzyme replacement therapy (ERT) in
Fabry’s disease. Results from independent ther-
apy studies are indeed promising: the infusion of
enzyme preparation seems to be well tolerated
and effective in catabolizing the lipid deposits
(13, 14). This ERT could be one of the first
examples for causal treatment of LVH. The avail-
ability of genetically engineered enzyme offers an
effective targeted treatment approach, but also
emphasizes the need for surrogate markers to
monitor the efficacy of ERT. Few data are until
now available on the impact of therapy on car-
diac involvement (15, 16). In this study, we aimed
to characterize left ventricular diastolic function
by Doppler echocardiography in asymptomatic
patients with Fabry cardiomyopathy and to
detect the impact of ERT on myocardial hyper-
trophy and on left ventricular function.
Materials and methods
Study population
Between July and December 2001, 20 subjects
from six families with Fabry’s disease were
screened at the Nephrology Department of Med-
ical School ‘Federico II’ of Naples. Two male
subjects did not have the mutation, one affected
male refused the study (he was a dialysis patient
and hemiplegic after a stroke episode). Eleven
subjects (seven males, four females) were identified
as affected by Fabry cardiomyopathy: as two
female patients were not eligible, due to atrial
fibrillation, nine patients were enrolled in the
study. The remaining six subjects were female
(one was 46 years old, three were under 20 years
of age, two were over seventy) and did not show
any evidence of Fabry’s disease throughout the
observation period of the study. The Fabry car-
diomyopathy was defined by echocardiographic
signs of increased thickness of the interventricular
septum and/or LV posterior wall. The diagnosis
of Fabry’s disease was confirmed by peripheral
blood a-galactosidase activity measurement, less
than 1.5 nmol/ml/h (normal: 8–19), in male
patients. Causal mutation was identified by direct
sequencing in all six families. Each patient
underwent a detailed clinical and instrumental
screening of assessment of Fabry’s disease
manifestations, including neurological, ophthal-
mologic, dermatological, renal, and cardiac
evaluation. After informed consent and approval
by the ethics committee of our institution, the
patients were treated with ERT, consisting of intra-
venous infusion of recombinant a-galactosidase A
(r-haGalA; agalsidase b; Fabrazyme1; Genzyme,
Cambridge, MA) at the dose of 1mg/kg/BW every
2weeks. Before starting ERT and after 6 and 12
months, all patients underwent a complete electro-
cardiographic and echocardiographic evaluation in
order to detect the effect of ERT on left ventricular
mass and function. Ten healthy subjects, age- and
gender-matched, were studied as the control group
for the basal evaluation of left ventricular function.
Echocardiography
Echocardiographic studies were performed by the
same operator using an ultrasound system (Sonos
2000, Hewlett-Packard, Andover, MA) equipped
with a 2.5MHz transducer, with the patient held
in left lateral decubitus.
Left ventricular chamber dimensions, septum,
and posterior wall thickness were measured utiliz-
ing two-dimensional guided M-mode recordings.
The images were stored on videotape and reading
was made in a blinded fashion by two independ-
ent observers (LS and MP), unaware of the tem-
poral sequence of the recordings. Each observer
read the all the 37 exams twice and intraobserver
reproducibility was calculated. Left ventricular
mass was calculated by the Penn Convention
based on 3–5 averaged measurements (17). Left
ventricular mass index was obtained by dividing
left ventricular mass by body surface area.
LVH was considered to be present if left ven-
tricular (LV) mass was above 130 g/m2 for male
and above 110 g/m2 for female. Relative wall
thickness (RWT) was calculated as (IVSthþ
PWth)/LVdd where IVSth and PWth and LVdd
indicated thickness of interventricular septum, LV
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posterior wall and internal diameter of the left
ventricle at the end of diastole, respectively. Left
ventricular concentric remodeling or concentric
hypertrophy was defined as RWT> 0.45. LV
volumes were measured with an application of
the biplane Simpon’s rule (18). Fractional short-
ening (FS) and ejection fraction were used as meas-
ures of LV systolic function.
The transmitral flow velocities were obtained
by pulsed Doppler interrogation, from a four-
chamber apical view, with the sample volume
placed at the level of the mitral valve leaflet tips.
Continuous wave Doppler echocardiography was
used to simultaneously obtain the transmitral
flow velocity curve and aortic valve closure
click. The pulmonary vein flow velocities were
recorded with the sample volume 0–1 cm into
the right superior pulmonary vein. Continuous
wave Doppler echocardiography was used to
simultaneously obtain the transmitral flow velo-
city curve and aortic valve closure click. Doppler
velocity curves were recorded at a horizontal
sweep speed of 100mm/s on videotape with the
patient held in expiration and measured by two
observers using electronic pointer device. For
each measurement, three consecutive beats were
averaged. The transmitral flow velocity curve was
analyzed for the measurement of early diastolic
(E) and late diastolic (A) peak velocities, the
deceleration time of the mitral E wave velocities
(DT), and the mitral A duration. The ratio
between early diastolic peak velocity and late
diastolic peak velocity on the mitral flow velocity
curve was also calculated (E/A ratio). Isovolumic
relaxation time (IRT) was measured as the inter-
val from the aortic closure click to E wave onset.
The pulmonary vein flow velocity curves was
analyzed for measurement of the peak velocity
and velocity–time integral (VTI) of systolic
(PVs) and diastolic (PVd) forward waves. The
peak velocity and the duration of the pulmonary
venous flow wave at atrial contraction (PVa) were
also determined. Finally, the difference between
the duration of PVa and the duration of A (
duration) was calculated. Reproducibility of
Doppler measurements from our laboratory has
been previously reported (19).
Statistical analysis
Continuous data are expressed as mean SD. To
assess the interobserver variability for the LV
measurements, the Pearson correlation coefficient
was calculated. Moreover, the percent difference
between the measurements made by the two
observers was calculated as the numerical average
of the absolute difference between two measure-
ments divided by the mean.
Student t-test and repeated measures analysis of
variance (ANOVA) were performed to compare the
Fabry patients and the control group and to
detect changes over time during ERT, respect-
ively. A two-tailed p-value< 0.05 was considered
statistically significant.
Results
Demographic data, clinical characteristics, symp-
toms of cardiac involvement, and extracardiac
manifestations of the nine patients included in
the study are reported in Table 1. In all patients,
a-galactosidase A enzymatic activity was very
low. None of the patients had symptoms of
heart failure. Extracardiac manifestations were
present in all patients. Acroparesthesias caused
by peripheral nerve lesions were present in six
patients. Skin lesions in the form of angiokerato-
mas were present in five patients, with localiza-
tion in lips, fingertips, palm of the hands, and
toes. Hypohidrosis with heat intolerance was pre-
sent in six patients. In all but two of the patients,
a renal impairment was documented, two patients
were on maintenance hemodialysis, and one
received a renal transplant 8 years prior to the
start of ERT. Two patients were hypertensive,
and only one was treated with angiotensin-
converting enzyme inhibitors at least 10 months
before starting ERT. In all patients, blood pres-
sure values and the anti-hypertensive drugs were
not changed during the observation period.
In the Table 2, the mean values of the echocar-
diographic and Doppler variables of control and
Fabry patients at baseline are listed. All patients
had interpretable Doppler recordings of trans-
mitral flow and pulmonary flow velocity curves.
As compared with the control group, the patients
with Fabry’s disease had increased thickness of
the interventricular septum and of the LV poster-
ior wall and increased LV mass index and RWT,
while LV end-diastolic and end-systolic dimen-
sions, LV fractional shortening and LV ejection
fraction were similar. In eight patients, a LV
concentric hypertrophy was detectable, while
one patient showed a concentric remodeling with-
out an abnormally increased mass.
The mean values of E/A ratio, DT, and IRT were
similar in the two groups; patients with Fabry’s
disease, however, had greater peak velocity and
VTI of PVa, and a greater  duration. Therefore,
in spite of the lack of abnormalities in Doppler
parameters of early left ventricular filling, presence
of diastolic dysfunction could be detected at
baseline.
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ERT did not induce changes in heart rate
(RR¼ 1033 108ms, 1016 55ms, 1001 103ms
at baseline and after 6 and 12 months of ERT,
respectively). No significant change was observed
in LV internal diameters (LVdd¼ 49 6mm,
48 3mm, 50 6mm; LVsd¼ 29 5mm,
29 6mm at baseline and after 6 and 12 months of
ERT, respectively), in FS (41 0.06%, 40 0.05%,
42 0.08%, at baseline and after 6 and 12 months
of ERT, respectively) and in LV ejection fraction
(56 4%, 57 6%, 59 4.5%, at baseline and
after 6 and 12months of ERT, respectively). Results
showed a slight but non-significant decrease in
the LV posterior wall thickness (13.3 1.6mm,
13 2.5mm, 12.4 1.5mm at baseline and after 6
and 12 months of ERT, respectively) and a signifi-
cant decrease in interventricular septum thickness,
in RWT and LV mass index (Fig. 1a,b,c). After 12
months of treatment with algasidase b, left ventri-
cular mass index (LVMi) was significantly reduced
in all but two of the patients (Fig. 1d). One of them
had left ventricular concentric remodeling (with
only an initial cardiac involvement), whereas the
other had a renal transplant with a history of severe
hypertension in the past and a marked increase of
left ventricular mass.
With regard to echo-Doppler-derived variables
IRT (86 17ms, 90 21ms, 82 16ms at base-
line and after 6 and 12 months of ERT, respect-
ively) and DT (248 70ms, 230 48ms,
234 60ms at baseline, and after 6 and 12 months
of ERT, respectively), PVs, PVd did not change
during the 12 months of treatment. There was a
Table 2. Echocardiographic and Doppler measurements in
Fabry patients at baseline
Variable Control Fabry patients
LA dimension (mm) 34 3.5 39.2 6.6a
Ao diameter (mm) 32 2.3 37.9 4.4
IVSth (mm) 9.1 1.6 13.9 2.2a
PWth (mm) 8.9 1.8 13.3 1.4a
LVdd (mm) 49 3.5 49.5 6.2
LVsd (mm) 27 2.8 29.1 5.4
RTW 0.39 0.03 0.54 0.10a
LVMi (g/m2) 84.4 21 183 44.5a
FS (%) 42.4 2.5 41 0.06
LV ejection fraction (%) 66 4 56.2 4.2
RR interval (ms) 940 38 1133 108.4
E/A ratio 1.2 0.9 1.38 0.5
DT (ms) 188 6 248 70a
IRT (ms) 85 8 92.5 17
PVs (cm/s) 55 14.4 56.8 12.2
PVd (cm/s) 59 11.5 49.3 12
PVa (cm/s) 22.1 4 36.1 8.4a
PVs VTI (cm) 13.7 2.4 15.7 2.28
PVd VTI (cm) 11 1.8 12.1 1.89
PVa VTI (cm) 1.3 0.08 2.52 0.70a
 duration (ms) 9 3.5 8.6 10.3a
ap< 0.05 (minimum) control subjects vs Fabry patients.
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slight decrease in PVa (32.6 8.46 cm/s,
29.5 6.64 cm/s, 28.5 6.64 cm/s at baseline and
after 6 and 12 months of ERT, respectively) and
VTI PVa (2.52 0.70 cm, 2.23 0.62 cm,
2.21 0.52 cm at baseline and after 6 and
12months of ERT, respectively), while E/A ratio
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Fig. 1. Echocardiographic parameters before and after 6 and 12 months of treatment with Fabrazyme. (a) Thickness of
interventricular septum (IVSth), (b) Relative wall thickness (RWT), (c) LVMi, (d) Individual changes in LVMi. Fabry patients
baseline vs control subjects (*p< 0.05), 12 months of enzyme replacement therapy (ERT) vs baseline (**p< 0.01).
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Fig. 2. Echo-Doppler parameters before and after 6 and 12 months of treatment with Fabrazyme. (a) E/A ratio and (b)  duration.
Fabry patients baseline vs control subjects (*p< 0.05), 12 months ERT vs baseline (**p< 0.01).
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and duration resulted significantly reduced dur-
ing therapy (Fig. 2). After one year of ERT, only
one patient exhibited a reverse pulmonary vein
flow velocity wave longer than mitral A wave.
Reproducibility
In the Table 3, the mean values of the readings
made by the two observers and for the interven-
tricular septum thickness, LV posterior wall thick-
ness, LVdd and LV mass index and interobserver
variability are shown. Interobserver variability
was expressed as percent difference of the meas-
urements and the Pearson correlation coefficient.
Discussion
During the past decade, the safety and the efficacy
of ERT for the lysosomal storage disease, Gaucher
type 1, have been demonstrated: the infusion of
recombinant acid b glucosidase is able to meta-
bolize the accumulated substrate and reverse the
disease-related abnormalities (20, 21) and is repre-
senting the standard of treatment for this disorder.
A report by the International Collaborative Fabry
Disease Study Group demonstrated the efficacy of
treatment with agalsidase b to reverse the accumu-
lation of microvascular endothelial deposits of
globotriaosylceramide in the kidney, heart, and
skin in patients with Fabry’s disease (13). Long-
term, double-blind, controlled studies would be
necessary in order to demonstrate the impact of
ERT on the prevention and, possibly, the rever-
sion of organ damage in Fabry’s disease. However,
the availability on the market of enzyme and its
effectiveness in removing lipid deposition (13)
makes very hard and even unethical to perform
such a study. Furthermore, based upon former
studies on the effect of therapy on LVH (22),
hundreds of patients in each arm would be necess-
ary to demonstrate its efficacy with such a pro-
tocol. The present study indicates that ERT in
patients with Fabry cardiomyopathy after 12
months of treatment reduces left ventricular mass
and ameliorates the left-ventricular stiffness, in
comparison with the basal condition.
The enzymatic defect of Fabry’s disease leads to
the accumulation of uncleaved glycosphingoli-
pids primarily but non-exclusively in the vascular
endothelium of skin, kidney, nervous system, eye,
and heart (2–7). Cardiac abnormalities are com-
mon and may be the only clinical manifestation
of disease in some patients (6, 8). The cardiomyo-
pathy in Fabry’s disease is a progressive hyper-
trophic infiltrative cardiomyopathy, with peculiar
features: glycosphingolipids lysosomal storage, in
fact, represents about 1% of the increase in left
ventricular mass (23, 24). Although globotriao-
sylceramide is the main glycosphingolipid to
accumulate, glycolipid biosynthesis and other
cellular pathways may also be deregulated. Other
sphingolipids that mimic the biological function
of cytokines, growth factors, and stress-signaling
molecules, accumulate in tissues and could act as a
second messenger and potentiate the hypertrophy
of the myocardium (2, 9). Of note, increased
plasma endotelin-1 levels have been reported
(25). Therefore, hypertrophic cardiomyopathy in
Fabry’s disease is due to a lysosomal storage and
to a true increase in heart muscle mass, related to
an additional neurohormonal activation.
Although most of Fabry patients do not experi-
ence symptoms until late in the disease course,
LVH may cause congestive heart failure, myocar-
dial ischemia, life-threatening arrhythmias, and
death. Cardiac involvement represents, thus, the
first cause of death for this disease (2–5). To date,
few studies suggest a positive effect of ERT on
LVH. A randomized trial by US National Insti-
tutes of Health demonstrated a decrease in QRS-
complex duration after ERT, suggesting an
improvement in intraventricular conduction
and/or a decrease in LV mass (14). In the present
study, echocardiography has been utilized to
assess changes in left ventricular mass. In order
to maximize the reliability of the method, we have
accurately tested the reproducibility of the meas-
urements with a blinded reading made by two
independent observers. Results of the current
study, showing a decrease in LV mass of about
10%, are consistent with those recently published
by Weidemann et al. (16) and obtained using
magnetic resonance imaging. In all but two of
the patients, we observed a significant reduction
in left ventricular mass during treatment with
agalsidase b. One of the two patients had only
Table 3. Reproducibility: interobserver variability for echocardiographic measurements
Measurement Observer A Observer B Percent difference (%) Pearson correlation coefficient
IVSth (mm) 13.32 1.78 13.42 1.61 4.3 0.941
PWth (mm) 12.92 2.16 12.99 2.00 3.5 0.977
LVdd (mm) 47.7 2.69 48.10 2.56 2.4 0.893
LVMi (g/m2) 169.4 43.7 168.7 41.4 4.1 0.986
Values are mean standard deviation.
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left ventricular concentric remodeling without an
increased mass, this indicating that this patient
was in an early phase of Fabry cardiomyopathy.
The other patient had a renal transplant and a
history of severe hypertension with blood pressure
values non-optimally controlled by the therapy.
The presence of hypertension or of comorbidity
in such patients, requires specific therapeutic
measures and represents a potential confounding
factor in assessing whether ERT is effective. Con-
sidering the progressive nature of cardiac involve-
ment in Fabry’s disease, the lack of increase in left
ventricular mass over 12 months could be assumed
as a positive effect of the ERT.
To date, no study reported the effect of ERT on
Doppler parameters of late diastole in Fabry’s
disease patients. Doppler echocardiography is a
reliable tool to assess left ventricular diastolic
function. The analysis of transmitral and pulmon-
ary venous flow velocity waves at atrial contrac-
tion is a validated tool to non-invasively detect
the increase in left ventricular stiffness and end-
diastolic pressure. High LV resistance to filling in
late diastole, due to reduced ventricular compli-
ance, results in increased pressure into the left
atrium, yielding a prolongation of the duration
of reverse pulmonary vein flow at atrial systole.
Both pulmonary vein and mitral A duration are
related to ventricular compliance and they change
in an opposite manner. Differently from Doppler-
derived parameters of the first diastolic phase,
which are influenced by left ventricular systolic
function and are predictive of filling pressures
only in patients with depressed left ventricular
ejection fraction, Doppler measurements of late
diastole reflect left ventricular end-diastolic pres-
sure, regardless of systolic function. Therefore,
they are suitable for patients affected by Fabry
cardiomyopathy whose cardiac involvement is
characterized by LVH and diastolic dysfunction
in presence of preserved systolic function. As the
little overlap of values between patients with and
without increased LV end-diastolic pressure, the
difference in duration of the pulmonary venous
flow velocity wave and mitral flow velocity wave
at atrial contraction is an index clinically useful in
individual patients (12). Our results demonstrate
that left ventricular diastolic dysfunction may be
present in Fabry patients with myocardial hyper-
trophy even in absence of symptoms. Although
diastolic impairment was not able to limit daily
life activities, it is likely that it could become a
limiting factor for exercise capacity whenever a
greater exercise performance was required. The
exercise tolerance was not specifically addressed
in the present study and it should an important
subject for future studies. According to Doppler
evidence of increased filling pressure, Fabry
patients exhibited a larger left atrium, an anatomic
hallmark of diastolic dysfunction. High values of
LV end-diastolic pressure have been previously
observed in Fabry patients, with mutation in a-
galactosidase A gene and LVH (26).
ERT induced a significant improvement in dia-
stolic function, as demonstrated by the significant
reduction in the difference between the duration
of the pulmonary vein and mitral A wave at atrial
contraction, suggesting a decrease in the left ven-
tricular filling pressures. After 12 months of ther-
apy, only one patient exhibited a pulmonary vein
A wave longer than mitral A wave. This patient
was carrying a kidney transplant and did not
show the regression of the left ventricular mass.
The current results indicate the effectiveness of
the ERT in eliciting a reduction in left ventricular
stiffness along with a decrease in left ventricular
mass in Fabry cardiac disease. It is reasonable to
postulate that the decrease in left ventricular
mass, that we and others observed, and the
improvement in left ventricular compliance were
due to a reverse substrate storage in the lyso-
somes of myocardial cells. Histological clearance
of the deposits of globotraosylceramide in the
vascular endothelium of the heart has been demon-
strated after 20 weeks of ERT (13). In one case of
cardiac variant of Fabry’s disease and residual
a-galactosidase A activity, intravenous infusions
of galactose enhanced the stability and the residual
enzyme activity and induced a decrease in the
endomyocardial storage vacuoles along with a
reduction of left ventricular mass (27).
These data emphasize the role of ERT in Fabry
cardiomyopathy. However, although our results
are encouraging, they were obtained in patients
without evidence of hemodynamic compromise,
therefore long-term follow-up data are necessary
to ascertain the real impact of ERT on the natural
history of this disease and on the survival of
patients with Fabry’s disease.
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